|Bid||0.0950 x 0|
|Ask||0.1000 x 0|
|Day's Range||0.1000 - 0.1100|
|52 Week Range||0.0650 - 0.1800|
|Beta (5Y Monthly)||0.25|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 30, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.52|
/NOT FOR DISTRIBUTION TO U. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/VANCOUVER, BC, July 28, 2020 /CNW/ - Aequus Pharmaceuticals Inc.
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today a grant of 1,124,337 stock options to the Chief Operating Officer to replace the same number of previously issued options that expired on May 31, 2020. The terms of the stock options granted on June 4, 2020 are in accordance with the Company’s Stock Option Plan.
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three months ended March 31, 2020 (“First Quarter 2020”) and associated Company developments. "Today the Company reported record quarterly revenues of $579,450 for Q1 2020, a 76% increase in revenues compared to Q1 2019,” said Doug Janzen, Chairman and CEO of Aequus. Revenues in First Quarter 2020 were $579,450, an increase of 76% compared to revenue of $328,996 recognized in the three months ended March 31, 2019 (“First Quarter 2019”).